Clinical Trial Design: Statistical Options/Challenges Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Opportunities to Optimize Cancer Policies Panel Discussion

Nov

Today In Oncology

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Opportunities to Optimize Cancer Policies Panel Discussion

Phase III VOLGA Trial Explores Outcomes in Muscle Invasive Bladder Cancer

TALENT Neoadjuvant T-DXd in HER2-Low Early Breast Cancer

How Medicare Advantage and Traditional Medicare Influence Palliative and Hospice Care Implementation

Optimizing Treatment for Relapsed/Refractory Follicular Lymphoma

Study Reveals Distinct Cellular and Genetic Differences in Early-Onset Colorectal Cancer